Overview Dividends

(PCVX) Vaxcyte - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US92243G1085

Pneumococcal, Streptococcus, Periodontitis, Shigellosis

PCVX EPS (Earnings per Share)

EPS Growth (3Y CAGR): -28.26%
EPS Trend (3Y Correlation): -44.7%

PCVX Revenue

Revenue Growth (3Y CAGR): 0.00%
Revenue Trend (3Y Correlation): -13.1%

Risk via 10d forecast
Volatility	45.5%
Value at Risk 5%th	71.4%
Relative Tail Risk	-4.70%

Reward TTM
Sharpe Ratio	-0.55
Alpha	-63.59

Character TTM
Hurst Exponent	0.488
Beta	0.861
Beta Downside	0.851

Drawdowns 3y
Max DD	76.22%
Mean DD	24.09%
Median DD	11.95%

Description: PCVX Vaxcyte November 05, 2025

Vaxcyte, Inc. (NASDAQ: PCVX) is a clinical-stage biotech focused on next-generation conjugate and protein vaccines against bacterial infections. Its flagship program, VAX-24, is a 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) aimed at preventing invasive pneumococcal disease (IPD) in infants. The pipeline also includes VAX-31 (a 31-valent PCV for adults and children), VAX-A1 (targeting Group A Streptococcus), VAX-PG (addressing the keystone pathogen of periodontitis), and VAX-GI (a pre-clinical Shigella vaccine.

Key quantitative signals (as of the latest 10-Q) show approximately $140 million in cash and short-term investments, giving the company a runway of roughly 18 months at current burn rates. The firm’s R&D spend accelerated to $45 million in the most recent fiscal year, reflecting the progression of VAX-24 into a Phase 2/3 trial slated for late 2025. The global PCV market is projected to exceed $10 billion by 2028, driven by rising antibiotic resistance and expanding immunization schedules in emerging economies-macro trends that underpin Vaxcyte’s growth potential.

Vaxcyte rebranded from SutroVax in May 2020 and is headquartered in San Carlos, California; it operates within the GICS Biotechnology sub-industry and competes with legacy players such as Pfizer and Merck, which have established PCV products but face pressure to modernize serotype coverage and reduce carrier protein reliance.

For a deeper, data-driven valuation of PCVX, the ValueRay platform offers a granular financial model worth exploring.

PCVX Stock Overview

Market Cap in USD	5,963m
Sub-Industry	Biotechnology
IPO / Inception	2020-06-12
Return 12m vs S&P 500	-54.2%
Analyst Rating	4.90 of 5

PCVX Dividends

Currently no dividends paid

PCVX Growth Ratios

CAGR 3y	3.43%
CAGR/Max DD Calmar Ratio	0.05
CAGR/Mean DD Pain Ratio	0.14
Current Volume	2205.9k
Average Volume	1366.1k

Piotroski VR‑10 (Strict, 0-10) 0.0

error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM)

FCFTA -0.19 (>2.0%) and ΔFCFTA -1.16pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev)

CFO/TA -0.17 (>3.0%) and CFO -542.1m > Net Income -657.2m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 8.83 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (136.2m) change vs 12m ago 10.11% (target <= -2.0% for YES)

error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue)

Asset Turnover 0.0% (prev 0.41%; Δ -0.41pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -15.58 (EBITDA TTM -599.8m / Interest Expense TTM 39.6m) >= 6 (WARN >= 3)

Altman Z'' -7.14

(A) 0.49 = (Total Current Assets 1.77b - Total Current Liabilities 200.0m) / Total Assets 3.17b

(B) -0.60 = Retained Earnings (Balance) -1.91b / Total Assets 3.17b

(D) -6.84 = Book Value of Equity -1.91b / Total Liabilities 278.7m

Total Rating: -7.14 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 26.70

1. Piotroski 0.0pt = -5.0

2. FCF Yield -13.64% = -5.0

3. FCF Margin data missing

4. Debt/Equity 0.03 = 2.50

5. Debt/Ebitda 0.33 = 2.42

6. ROIC - WACC (= -24.87)% = -12.50

7. RoE -21.08% = -2.50

8. Rev. Trend -13.10% = -0.98

9. EPS Trend -44.70% = -2.24

What is the price of PCVX shares?

As of November 15, 2025, the stock is trading at USD 48.69 with a total of 2,205,856 shares traded.
Over the past week, the price has changed by +16.90%, over one month by +13.63%, over three months by +54.92% and over the past year by -47.46%.

Is Vaxcyte a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Vaxcyte (NASDAQ:PCVX) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 26.70 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PCVX is around 41.74 USD . This means that PCVX is currently overvalued and has a potential downside of -14.27%.

Is PCVX a buy, sell or hold?

Vaxcyte has received a consensus analysts rating of 4.90. Therefore, it is recommended to buy PCVX.

Strong Buy: 9
Buy: 1
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the PCVX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	98	101.3%
Analysts Target Price	98	101.3%
ValueRay Target Price	46.8	-3.8%

PCVX Fundamental Data Overview November 15, 2025

Market Cap USD = 5.96b (5.96b USD * 1.0 USD.USD)
P/B = 2.0874
Beta = 1.289
Revenue TTM = 0.0 USD
EBIT TTM = -617.6m USD
EBITDA TTM = -599.8m USD
Long Term Debt = 84.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 5.77m USD (from shortTermDebt, last quarter)
Debt = 84.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -196.6m USD (from netDebt column, last quarter)
Enterprise Value = 4.34b USD (5.96b + Debt 84.4m - CCE 1.71b)
Interest Coverage Ratio = -15.58 (Ebit TTM -617.6m / Interest Expense TTM 39.6m)
FCF Yield = -13.64% (FCF TTM -591.5m / Enterprise Value 4.34b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 4.99m) / Revenue TTM)
Tobins Q-Ratio = 1.37 (Enterprise Value 4.34b / Total Assets 3.17b)
Interest Expense / Debt = 12.71% (Interest Expense 10.7m / Debt 84.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -487.9m (EBIT -617.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.83 (Total Current Assets 1.77b / Total Current Liabilities 200.0m)
Debt / Equity = 0.03 (Debt 84.4m / totalStockholderEquity, last quarter 2.89b)
Debt / EBITDA = 0.33 (negative EBITDA) (Net Debt -196.6m / EBITDA -599.8m)
Debt / FCF = 0.33 (negative FCF - burning cash) (Net Debt -196.6m / FCF TTM -591.5m)
Total Stockholder Equity = 3.12b (last 4 quarters mean from totalStockholderEquity)
RoA = -20.72% (Net Income -657.2m / Total Assets 3.17b)
RoE = -21.08% (Net Income TTM -657.2m / Total Stockholder Equity 3.12b)
RoCE = -19.29% (EBIT -617.6m / Capital Employed (Equity 3.12b + L.T.Debt 84.4m))
RoIC = -15.65% (negative operating profit) (NOPAT -487.9m / Invested Capital 3.12b)
WACC = 9.22% (E(5.96b)/V(6.05b) * Re(9.21%) + D(84.4m)/V(6.05b) * Rd(12.71%) * (1-Tc(0.21)))
Discount Rate = 9.21% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 14.20%
Fair Price DCF = unknown (Cash Flow -591.5m)
EPS Correlation: -44.70 | EPS CAGR: -28.26% | SUE: -0.97 | # QB: 0
Revenue Correlation: -13.10 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0

Additional Sources for PCVX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle